CRISPR Therapeutics AG
CRSP
$57.67
-$2.33-3.88%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -250.07% | -23.85% | -64.98% | -16.64% | -141.76% |
| Total Depreciation and Amortization | 16.91% | -6.46% | -4.05% | -2.01% | -1.18% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 43.73% | -55.86% | 587.70% | 103.86% | -50.26% |
| Change in Net Operating Assets | 192.95% | 127.03% | -257.41% | -73.94% | 88.06% |
| Cash from Operations | -84.99% | 20.84% | -19.14% | -149.15% | 47.92% |
| Capital Expenditure | -103.54% | 66.21% | 83.45% | 71.43% | 65.58% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -64.45% | 26.17% | 155.54% | 79.86% | 231.43% |
| Cash from Investing | -64.85% | 26.22% | 155.14% | 79.80% | 229.93% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 589.82% | 2,978.49% | -- | -96.54% | -56.66% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 589.82% | 2,978.49% | 584.55% | -96.54% | -56.66% |
| Foreign Exchange rate Adjustments | 101.15% | -136.00% | 3,900.00% | 472.73% | -242.62% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -15.88% | 135.89% | 81.36% | -119.84% | 152.40% |